Rare Disease Trials: How to Find and Recruit Hard-to-Reach Participants

Rare disease trials face one major challenge from the start.

Finding the right patients.

Unlike common conditions, rare diseases have small, scattered populations. Patients may be spread across regions, misdiagnosed, or not actively connected to research opportunities.

This makes recruitment slower, more complex, and often unpredictable.

Why Rare Disease Recruitment Is So Difficult

The issue is not just low numbers.

It is also about visibility and access.

Patients with rare conditions often:

• Are widely dispersed across locations

• Sit outside traditional care pathways

• Have long diagnostic journeys

• Are not actively engaged in research networks

This creates a gap between where patients are and where trials are being run.

Why Traditional Recruitment Falls Short

Standard recruitment strategies do not always work here.

Broad outreach campaigns may generate interest, but not from eligible patients. Site-led recruitment may also struggle if those sites do not have direct access to the right population.

This often leads to:

• Slow enrolment

• High screening failure rates

• Extended timelines

For rare disease trials, a different approach is needed.

Start With Better Visibility

The first step is understanding where patients actually are.

Without this, recruitment becomes guesswork.

Access to real patient data allows research teams to:

• Estimate the true size of the eligible population

• Identify geographic clusters

• Plan site locations more effectively

TrialChoices supports this by enabling access to UK patient populations through healthcare providers, helping researchers identify suitable participants earlier.

Work Through Trusted Healthcare Pathways

Rare disease patients often rely heavily on their healthcare providers.

GPs, specialists, and consultants play a key role in diagnosis and ongoing care.

This makes healthcare pathways one of the most effective routes for recruitment.

Instead of relying only on external campaigns, a stronger approach includes:

• Working with GP practices

• Engaging secondary care providers

• Connecting with specialists who manage these conditions

Patients are more likely to respond when approached through trusted clinical relationships.

Focus on Precision, Not Volume

In rare disease trials, quality matters more than quantity.

Recruitment is not about reaching as many people as possible. It is about finding the right patients quickly.

This means:

1. Using clear, well-defined criteria

2. Matching patients accurately from the start

3. Reducing unnecessary screening

A more targeted approach improves efficiency and saves time.

The Role of Early Planning

Timing is critical.

Rare disease trials cannot afford delays caused by late planning.

Recruitment should be built into the study from the beginning, including:

• Feasibility based on real data

• Site selection aligned with patient locations

• Early identification of potential cohorts

TrialChoices focuses on faster study start-up and early cohort access, helping reduce the risk of slow recruitment later.

Why Location Still Matters

Even in global trials, location plays a big role.

Patients may exist, but if they are not near participating sites, recruitment slows down.

For rare diseases, this becomes even more important.

Better alignment between patient location and study sites can:

• Reduce travel barriers

• Improve participation rates

• Speed up enrolment

Using UK patient data helps identify where these patients are, allowing for smarter planning.

Overcoming Patient Awareness Barriers

Many rare disease patients are open to participating in research.

The challenge is awareness.

Patients may not know:

• That a trial exists

• That they are eligible

• How to get involved

This is where healthcare providers can make a difference.

When GPs or specialists introduce the opportunity, patients are more likely to consider participation.

Reducing the Burden on Patients

Rare disease patients often face complex care journeys.

Recruitment strategies should minimise additional burden.

This includes:

• Clear communication

• Simple referral processes

• Convenient study locations where possible

Making participation easier increases the likelihood of enrolment.

Signs Your Strategy Needs to Change

If your rare disease trial is facing challenges, look for these signs:

• Very slow initial recruitment

• Difficulty identifying eligible patients

• High drop-off during screening

• Limited response to outreach efforts

These usually point to gaps in access, not lack of demand.

A More Effective Recruitment Model

Successful rare disease recruitment combines several elements:

• Early access to patient data

• Strong links with healthcare providers

• Targeted patient identification

• Better alignment between sites and populations

TrialChoices helps bring these elements together by connecting research teams with UK healthcare networks and patient groups.

Final Thoughts

Rare disease trials are challenging, but they do not have to be unpredictable.

The key is shifting from broad, reactive recruitment to a more targeted and data-driven approach.

When research teams have better visibility into patient populations and stronger connections to healthcare pathways, recruitment becomes more manageable.

TrialChoices supports this by helping identify suitable UK patients earlier and connecting them to global research opportunities.

For rare disease studies, that can make all the difference.

Contact TrialChoices

If your rare disease trial needs better access to hard-to-reach patients, TrialChoices can help.

Call +44 (0) 07711 248 610  or email info@trialchoices.org to learn how to connect with UK patients faster and improve your recruitment strategy.